Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Duktales Carcinoma in situ

Ductal carcinoma in situ

  • 72 Accesses

Zusammenfassung

Das duktale Carcinoma in situ (DCIS) repräsentiert eine heterogene Gruppe intraduktaler neoplastischer Proliferationen innerhalb der Milchgänge. Mit der Einführung der Mammographie wird DCIS zunehmend häufiger diagnostiziert. Gruppierte Mikroverkalkungen sind das häufigste Leitsymptom der DCIS-Diagnose. DCIS wächst in duktal-segmentaler Form. Unvollständige Exzision eines DCIS führt häufig zu einem invasiven Mammakarzinom. Die Mastektomie ist eine sichere kurative Therapie des DCIS. Patientinnen mit einem kleinen lokalisierten DCIS können mit niedrigem Rezidivrisiko brusterhaltend behandelt werden. Detaillierte Mammographie und sorgfältige histologische Untersuchung sind hierfür notwendig, um Größe, Ausdehnung, Typ, Malignitätsgrad und die Resektionsränder zu beurteilen. Das wichtigste Ziel der operativen Therapie ist die vollständige Entfernung aller Herde. Bestrahlung und Tamoxifen kann das Risiko eines Rezidivs senken. Die interdisziplinäre Therapieplanung ist daher essenziell.

Abstract

Ductal carcinoma in situ (DCIS) represents a heterogeneous group of intraductal neoplastic proliferative lesions of the ductal system. The widespread use of mammography has resulted in a significant increase of DCIS diagnosis. Clustered microcalcificaction is the most common presentation of DCIS. The DCIS has a ductal-segmental distribution. Incomplete excision of DCIS lesion may progress to invasive breast cancer in many cases. Mastectomy of DCIS is associated with a high cure rate. Patients with a localized DCIS can safely be treated by breast conserving therapy. Detailed mammography and a meticulous histologic evaluation are essential to confirm the size, extension, type, grading and adequacy of the resection. The most important goal of surgery is the complete removal of the DCIS. Radiation and Tamoxifen can reduce the recurrence rate after breast-conserving surgery. The interdisciplinary therapy planning of DCIS is necessary.

This is a preview of subscription content, log in to check access.

Abb. 1a, b
Abb. 2a, b
Abb. 3a, b

Literatur

  1. 1.

    WHO (1981) Histological typing of breast tumors, 2nd edn. International histological classification of tumors, no. 2. World Health Organisation, Geneva

  2. 2.

    Lagios MD, Margolin FR, Westdahl PR et al. (1989) Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 63: 618–624

  3. 3.

    Solin LJ, Yeh It, Kurtz J et al. (1993) Ductal carcinoma in situ of the breast treated with breast-conserving surgery and definitive irradiation: Correlation of pathologic parameters with the outcomje of treatment. Cancer 71: 2532–2542

  4. 4.

    Silverstein MJ, Poller DN, Waisman JR et al. (1995) Prognostic classification of breast ductal carcinoma in situ. Lancet 345: 1154–1157

  5. 5.

    Fisher ER, Costantino J, Fisher B et al. (1995) Pathologic findings from the National Surgical Adjuvant Breast Protocol B-17: intraductal carcinoma (duct carcinoma in situ). Cancer 75: 1310–1319

  6. 6.

    Schwartz GF, Lagios MD, Carter D et al. (1997) Consensus conference on the classification of ductal carcinoma in situ. Cancer 80: 1798

  7. 7.

    National Cancer Institute, DCPC Surveillance Program (1995) Surveilance, Epidemiologic, and End Results (SEER) Program. Bethesda MD

  8. 8.

    Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C (1996) Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 275: 913–918

  9. 9.

    Tabar L, Gad A, Parsons WC et al. (2002) Mammographic appearances of in situ carcinomas. In : Silverstein MJ, Recht A, Lagios MD (eds) Ductal carcinoma in situ of the breast, 2nd edn. Lippincott Williams & Wilkins, Philadelphia Baltimore New York

  10. 10.

    Kettritz U, Rotter K, Schreer I et al. (2004) Stereotactic vacuum-assisted breast biopsy in 2874 Patients. A Multicenter Study. Cancer 2: 245–251

  11. 11.

    Page DL, Dupont WD, Rogers LW, Landenberger M (1982) Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 49: 751–758

  12. 12.

    Rosen PP, Braun D, Kinne D (1980) The clinical significance of pre-invasive breast carcinoma. Cancer 46: 919–925

  13. 13.

    Gapstur S, Morrow M, Sellers TA (1999) Hormone replacement therapy and risk of breast cancer with a favourable histology. Results of the IOWA Women’s Health study. JAMA 281: 2091–2097

  14. 14.

    Weiss HA, Brinton LA, Brogan D et al. (1996) Epidemiology of in situ and invasive breast cancer in women aged under 45. Br J Cancer 73: 1298–1305

  15. 15.

    Solin LJ, Recht A, Fourquet A at al. (1991) Ten-year result of breast conserving surgery and definitive irradiation for intraductal carcinoma(ductal carcinoma in situ) of the breast. Cancer 68: 2337–2344

  16. 16.

    Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA (1995) Continued local recurrence of carcinoma 15–25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 76: 1197–1200

  17. 17.

    Ohtake T, Abe R, Kimijima I et al. (1995) Intraductal extension of primary invasive breast carcinoma treated by breast conservative surgery. Computer graphic three-dimensional reconstruction of the mammary duct-lobular systems. Cancer 76: 32–45

  18. 18.

    Faverly D, Burgers L, Bult P, Holland R (1994) Three dimensional imaging of mammary ductal carcinoma in situ: clinical implications. Semin Diagn Pathol 11: 193–198

  19. 19.

    Holland R, Hendriks JH (1994) Microcalcifications associated with ductal carcinoma in situ: mammographic-pathologic correlation. Semin Diagn Pathol 11: 181–192

  20. 20.

    Silverstein MJ, Lagios MD, Craig PH et al. (1996) A prognostic index for ductal carcinoma in situ of the breast. Cancer 77: 2267–2274

  21. 21.

    Douglas-Jones AG, Gupta SK, Attanoos RL, Morgan JM, Mansel RE (1996) A critical appraisal of six modern classifications of ductal carcinoma in situ of the breast (DCIS): correlation with grade of associated invasive cancer. Histopathology 29: 397–409

  22. 22.

    Bethwaite P, Smithe N, Delahunt B, Kenwright D (1998) Reproducebility of new classification schemes for the pathology of ductal carcinoma in situ of the breast. J Clin Pathol 51: 450–454

  23. 23.

    Silverstein MJ, (2002) The university of Southern California / Van Nuys Prognostic Index. In: Silverstein MJ, Recht A, Lagios MD (eds) Ductal carcinoma in situ of the breast, 2nd edn. Lippincott Williams & Wilkins, Philadelphia Baltimore New York

  24. 24.

    Bradley SJ, Weaver DW, Bouwman DL (1990) Alternatives in the surgical management of in situ breast cancer. A meta-analysis of outcome. Am Surg 56: 428–432

  25. 25.

    Page DL, Lagios MD (1995) Pathologic analysis of the National Surgical Adjuvant Breast Project (NSABP) B 17 trial : unanswered questions remaining unanswered considering current concepts of ductal carcinoma in situ. Cancer 75: 1219–1222

  26. 26.

    Lagios MD (2002) Der Einfluss der histopathologischen Gewebeaufbereitung auf das Ergebnis beim duktalen In-situ-Karzinom. In: Untch M, Sittek H, Bauernfeind I, Konecny G, Reiser M, Hepp H (Hrsg) Diagnostik und Therapie des Mammakarzinoms—State of the Art. Zuckschwerdt, München Wien New York

  27. 27.

    Silverstein MJ, Lagios MD, Groshen S (1999) The influence of margin width on local control of ductal carcinoma in situ of the breast. NEngl J med 340: 1455–1461

  28. 28.

    Lagios MD, Silverstein MJ (1997) Ductal carcinoma in situ. The success of breast conservation therapy: a shared experience of the two single institutional nonrandomised prospective studies. Surg Oncol Clins N Am 6: 385–392

  29. 29.

    Tulusan AH, Bühner M, Folger M et al. (1998) Die Therapie des Carcinoma ductale in situ der Mamma. Geburtsh Frauenheilk 58: 363

  30. 30.

    Tulusan AH, Bühner M, Dresel V, Lang N (2000) Die Therapie des Carcinoma ductale in situ der Mamma. In: Untch M, Sittek H, Bauernfeind I, Konecny G, Reiser M, Hepp H (Hrsg) Diagnostik und Therapie des Mammakarzinoms — State of the Art. Zuckschwerdt, München Wien New York

  31. 31.

    Fisher B, Dignam J, Wolmark N et al. (1998) Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16: 441–452

  32. 32.

    Fisher B, Costantino J, Wickerham DL et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371–1388

  33. 33.

    Fisher B, Dignam J, Wolmark N (1999) Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353: 1993–2000

  34. 34.

    Houghton J, George WD, Cuzick J et al., UK Coordinating Committee on Cancer Research (UKCCCR), Ductal Carcinoma in situ (DCIS) Working Party, DCIS trialists in the UK, Australia, and New Zealand (2003) Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362: 95–102

Download references

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Correspondence to Prof. Dr. A. H. Tulusan.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Tulusan, A.H., Bühner, M., Parchent, H. et al. Duktales Carcinoma in situ. Gynäkologe 38, 65–74 (2005). https://doi.org/10.1007/s00129-004-1637-1

Download citation

Schlüsselwörter

  • Mammakarzinom
  • Intraduktales Karzinom
  • Carcinoma in situ
  • Mastektomie

Keywords

  • Breast cancer
  • Intraductal carcinoma
  • Carcinoma in situ
  • Mastectomie